Kymera Therapeutics (KYMR) Receivables (2020 - 2026)

Kymera Therapeutics (KYMR) has reported Receivables for 6 consecutive years, with $40.0 million the latest figure, recorded in Q2 2025.

• In Q2 2025, Receivables rose 1073.71% year-over-year to $40.0 million; the TTM figure through Jun 2025 stood at $40.0 million (up 1073.71% YoY), while the FY2024 annual figure was $1.9 million, down 91.61% from the prior year.
• Receivables steadied at $40.0 million in Q2 2025 per KYMR's latest filing, from $40.0 million in the prior quarter.
• Across five years, Receivables topped out at $40.0 million in Q1 2025 and bottomed at $270000.0 in Q4 2021.
• Historically, Receivables has averaged $9.1 million across 5 years, with a median of $4.4 million in 2022.
• Annual changes were most pronounced in 2022 — Receivables jumped 1765.56% — and 2024, when it sank 91.81%.
• Kymera Therapeutics' Receivables stood at $270000.0 in 2021, then surged by 1765.56% to $5.0 million in 2022, then surged by 347.93% to $22.6 million in 2023, then tumbled by 91.81% to $1.8 million in 2024, then surged by 2065.67% to $40.0 million in 2025.
• Business Quant data shows KYMR's Receivables at $40.0 million in Q2 2025, $40.0 million in Q1 2025, and $1.8 million in Q4 2024.